Combination agents target early, late stages of allergy

Article

Ophthalmic drops that combine immediate antihistamine relief with prophylactic care in the form of mast cell inhibition and eosinophil blockage are the mainstay of therapy for allergic conjunctivitis.

Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
Related Content
CGTLive®’s Weekly Rewind – April 19, 2024

CGTLive®’s Weekly Rewind – April 19, 2024

April 19th 2024
Article

Review top news and interview highlights from the week ending April 19, 2024.

FDA to Investigate Risk of T-Cell Malignancy After CAR T-Cell Therapy

FDA Requires Boxed Warnings for Secondary Cancer for Approved CAR-T Therapies

April 19th 2024
Article

The FDA has requested that black box warnings related to secondary cancer risks be added to all 6 CAR-T therapies currently on the market.

Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, Sierra Eye Associates and Clinical Professor, Reno School of Medicine, University of Nevada

MCO-010 Phase 2b Data Supports BLA Submission for Retinitis Pigmentosa

April 19th 2024
Article

Nanoscope Therapeutics received feedback from the FDA endorsing significant change in BCVA as a primary endpoint supporting approval.

Pierre-Yves Berclaz, MD, PhD, the executive vice president and chief science and medical officer of Ferring Pharmaceuticals

Ferring Launches 3 New Clinical Trials for Marketed Bladder Cancer Gene Therapy Adstiladrin

April 18th 2024
Article

The 3 new clinical trials will take place in the United States and are intended to increase the amount of accumulated data supporting the use of Adstiladrin in NMIBC.

Nancy J. Newman, MD

Gene Therapy Improves Vision Recovery in LHON Over Idebenone, Natural History

April 18th 2024
Article

Data from a meta-analysis of 3 groups of patients were presented at AAN 2024.

A Slow Embrace: Hemophilia's Gradual Adoption of Gene Therapy

A Slow Embrace: Hemophilia's Gradual Adoption of Gene Therapy

April 17th 2024
Article

For World Hemophilia Day, CGTLive takes a look at how the hemophilia field has adapted to the introduction of gene therapy to the treatment landscape.

© 2024 MJH Life Sciences

All rights reserved.